Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vertex Pharmaceuticals and Janssen Pharmaceutica, a Johnson & Johnson company, have agreed to collaborate to develop and commercialize Vertex' investigational hepatitis C virus protease inhibitor, VX-950.
Subscribe to our email newsletter
Under the agreement, Janssen will have exclusive rights in Europe, South America, the Middle East, Africa and Australia, and Vertex will retain exclusive commercial rights to VX-950 in North America. Tibotec Pharmaceuticals, another Johnson & Johnson company, will lead the development and commercialization of VX-950 for Janssen.
Vertex will receive an upfront payment of $165 million upon signing the contract. In addition, Vertex could receive up to $380 million based on successful development and launch of VX-950 in the territories. The agreement also includes a royalty on product sales in Europe and other territories outside of North America and the Far East.
Vertex and Tibotec also announced that they will establish a global health initiative to increase the prevention, diagnosis, treatment and cure of hepatitis C virus infection to be principally directed toward developing countries.